Health Sector Buzz: AG1 Sale Speculation, Genetic Weight-Loss Links, and More
Published on: April 12, 2026, 2:29 a.m. | Source: Devdiscourse
Health sector updates include AG1 exploring business sale options, genetic links to effective GLP-1 obesity drugs, Amgen's lung cancer drug approval in China, Kennedy's vaccine advisory panel focusing on risks, Replimune's skin cancer drug facing FDA rejection, and Abbott's $70M jury verdict over infant formula risks.
